The treatment options for systemic light chain amyloidosis (AL) are currently widening in an
unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as …

Amyloidosis is a disorder of protein misfolding and metabolism in which insoluble fibrils are
deposited in various tissues, causing organ dysfunction and eventually death. Out of the 60 …

Amyloidosis is a systemic disease characterized by the accumulation of insoluble
aggregates in various organs, leading to parenchymal damage. When these amyloid fibrils …

The most direct metric of the systolic performance of the heart is the quantity of blood ejected
by the left ventricle during a single systole (ie, the stroke volume). The stroke volume adapts …

Subclinical alterations in myocardial structure and function occur early during the natural
disease course. In contrast, clinically overt signs and symptoms occur during late phases …

Cardiac involvement is the foremost determinant of the clinical progression of amyloidosis.
The diagnostic role of cardiac magnetic resonance (CMR) imaging in cardiac amyloidosis …

Systemic AL amyloidosis is a rare complex hematological disorder caused by clonal plasma
cells which produce amyloidogenic immunoglobulins. Outcome and prognosis is the …

11C-Pittsburgh compound B (PiB) PET/CT visualizes the amount of myocardial amyloid
deposit and can be used to prognosticate patients with amyloid light-chain (AL) cardiac …

Objectives To evaluate the prognostic value of radiomics features based on late gadolinium
enhancement (LGE) cardiac magnetic resonance (CMR) images in patients with cardiac …

Aims: The differentiation of left ventricular (LV) hypertrophic phenotypes is challenging in
patients with normal ejection fraction (EF). The myocardial contraction fraction (MCF) is a …